Biopharmx Corp (BPMX) Sees Large Increase in Short Interest

Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,768,921 shares, an increase of 12.9% from the December 14th total of 1,567,215 shares. Based on an average daily volume of 3,808,899 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.0% of the shares of the company are short sold.

In related news, Director Stephen Morlock sold 1,125,027 shares of the business’s stock in a transaction on Monday, October 22nd. The stock was sold at an average price of $0.18, for a total transaction of $202,504.86. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NYSEAMERICAN BPMX opened at $0.12 on Friday. Biopharmx has a twelve month low of $0.05 and a twelve month high of $0.38.

Biopharmx (NYSEAMERICAN:BPMX) last announced its earnings results on Thursday, December 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.02 million.

COPYRIGHT VIOLATION NOTICE: “Biopharmx Corp (BPMX) Sees Large Increase in Short Interest” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.chaffeybreeze.com/2019/01/11/biopharmx-corp-bpmx-sees-large-increase-in-short-interest.html.

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Recommended Story: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply